Shares of Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.04, with a volume of 40,045 shares changing hands.
Mateon Therapeutics Trading Down 4.2 %
The stock’s fifty day simple moving average is $0.03 and its 200 day simple moving average is $0.03.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Articles
- Five stocks we like better than Mateon Therapeutics
- What Are Dividend Contenders? Investing in Dividend Contenders
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Are Dividends? Buy the Best Dividend Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is the Hang Seng index?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
